Author

N. Palmisano

Observed name: Neal Palmisano

Institution: Thomas Jefferson University Hospital

Observed institutions: Pennsylvania State University, Thomas Jefferson University Hospital, Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center

OpenAlex ID: A5032700328

SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: a TRIAL OF THE ECOG‐ACRIN CANCER RESEARCH GROUP (E4412)

2017 · C.S. Diefenbach, F. Hong, et al. · Hematological Oncology · 27

Extended Follow‐up of a Phase I Trial of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed Hodgkin Lymphoma: a Trial of the Ecog‐acrin Research Group (e4412)

2019 · C.S. Diefenbach, F. Hong, et al. · Hematological Oncology · 12

Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.

2018 · Catherine S. Magid Diefenbach, Fangxin Hong, et al. · Journal of Clinical Oncology

Works count: 3

Citation count: 39

H-index: 2

I10-index: 2